# Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

> **NCT04463251** · PHASE2 · COMPLETED · sponsor: **R-Pharm Overseas, Inc.** · enrollment: 102 (actual)

## Conditions studied

- Acute ST Segment Elevation Myocardial Infarction

## Interventions

- **BIOLOGICAL:** RPH-104 80 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04463251
- **Lead sponsor:** R-Pharm Overseas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2021-11-03
- **Final completion:** 2022-10-10
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04463251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04463251, "Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04463251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*